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Abstract: Aim The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have
poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA), and those with
scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized
that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2
scores >2 than to patients with lower scores. Methods and results We analyzed the Phase III dataset of
the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation
(GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and
฀1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions
to determine the probability of VKA prescription among anticoagulated patients with baseline SAMe-
TT2R2 score >2 and ฀2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) were prescribed
VKA and 12,637 (72.4%) a NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581
(32.0%) had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with
SAMe-TT2R2 scores >2 and 27.5% in those with scores ฀2. Conclusions The lack of clear association
between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy
and safety profiles between NOACs and VKAs, as well as to the absence of trial evidence that a SAMe-
TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact
on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized
controlled trial.
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Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor 
anticoagulation control during anticoagulation with vitamin K antagonists (VKA), and those with scores 
>2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in 
clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 
than to patients with lower scores.  
Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral 
Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective 
global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline 
clinical characteristics and antithrombotic prescriptions to determine the probability of VKA prescription 
among anticoagulated patients with baseline SAMe-TT2R2 score >2 and ≤2. Among 17,465 
anticoagulated patients with AF, 4,828 (27.6%) were prescribed VKA and 12,637 (72.4%) a NOAC: 11,884 
(68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) had scores >2. The proportion of patients 
prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores 
≤2. The adjusted probability for VKA prescription in patients with scores >2 vs. score <=2 was 0.907 
(95%CI: 0.856-0.961).  
Conclusions: The lack of clear association between the SAMe-TT2R2 score and anticoagulant selection 
may be attributed to the relative efficacy and safety profiles between NOACs and VKAs, as well as to the 
absence of trial evidence that a SAMe-TT2R2-guided strategy for the selection of the type of 
anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter 
hypothesis is currently being tested in a randomized controlled trial. 
Clinical trial registration: URL: https://www.clinicaltrials.gov / Unique identifier: NCT01937377, 
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For many decades, vitamin-K antagonists (VKA) were the only anticoagulant choice for patients with 
non-valvular atrial fibrillation (NVAF). The achievement and maintenance of a therapeutic international 
normalized ratio (INR) in VKA-treated patients can be challenging due to numerous VKA-related 
limitations such as narrow therapeutic window, need for frequent INR measurements with consequent 
dose adjustments, and food-drug and drug-drug interactions. 
Common clinical factors determine if a patient can achieve effective and safe anticoagulation control on 
VKAs.  The SAMe-TT2R2 score was developed to help identify those at high-risk for poor anticoagulation 
control and thus higher risk of stroke or peripheral embolism as estimated by the time in therapeutic 
INR range (TTR).  The SAMe-TT2R2 score consists of the following: Sex (female), Age (<60 years); Medical 
history (≥2 of the following: hypertension, diabetes, coronary artery disease/myocardial infarction, 
peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, hepatic or renal 
disease); Treatment (interacting drugs, like amiodarone for rhythm control) [all 1 point]; current 
Tobacco use (2 points) and Race (2 points for non-Caucasian)
1
. Patients with a SAMe-TT2R2 score >2 
could best avoid a “trial of VKA” and start directly with a non-vitamin-K-antagonist oral anticoagulant 
(NOAC).      
The recent 2018 CHEST Guideline and Expert Panel Report on antithrombotic therapy in patients with 
atrial fibrillation suggest that the SAMe-TT2R2 score could be used to aid decision-making: patients with 
a score of >2 points are prone to low TTR while on VKA and can be monitored more closely with more 
frequent INR measurements or can be supported with more intensive education or counselling to 
improve TTR.  Alternatively, if there are concerns, they may skip a “trial of VKA” and start directly with a 
non-vitamin-K antagonist oral anticoagulant (NOAC)
2
. 
In this context, we hypothesized that VKAs may be less frequently prescribed in patients with non-
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We tested this hypothesis in a large, contemporary, prospective, global registry of newly diagnosed 














The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation 
(GLORIA-AF) was designed to generate evidence on patients with recently diagnosed NVAF treated in 
routine clinical practice. The aim of this multinational, multicenter, prospective, non-interventional 
registry is to provide long-term effectiveness and safety data on NOAC and VKA for stroke prevention in 
patients with NVAF in nearly 50 countries
3
. 
The design of GLORIA-AF, a global, non-interventional registry program with 3 phases, has been 
described in detail previously
3
. Phase III consists of a cross-sectional and comparative analyses part 
involving a 3-year follow-up of all patients independent of antithrombotic therapy. Ethical approvals 
were obtained from the Institutional Review Boards as required at participating sites. The GLORIA-AF 
study is listed at Clinicaltrials.gov (NCT01937377, NCT01468701 and NCT01671007). 
The phase III of GLORIA-AF enrolled adult patients with newly diagnosed NVAF (i.e. NVAF diagnosed 
within 3 months of the baseline visit; Latin America < 4.5 months) and a CHA2DS2-VASc score of ≥1 
between 2014 and 2016. Patients with mechanical heart valves, prior VKA therapy for >60 days, life-
expectancy ≤1 year at recruitment, a comorbidity other than NVAF for which chronic use of VKAs is 
indicated and NVAF due to a generally reversible cause were excluded. The CHADS2 and CHA2DS2-VASc 
scores were used to assess the thromboembolic risk of the patients. The HAS-BLED bleeding score was 
used to assess bleeding risk
4
. Patients were recruited from outpatient settings from university hospitals, 
community hospitals, specialist offices and general practice offices. Sites were chosen to reflect 
physicians who typically identify and manage patients with newly diagnosed NVAF cases in each 
participating country. 
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All clinical data were collected and processed using a web-based external vendor managed Infosario 
Outcome EDC ® system to ensure that data was complete, accurate, internally consistent, logical and in 
compliance with the requirements of the protocol. Study data were entered into the EDC system by the 
study staff using a secured network and the study physician electronically signed the case report forms 
to confirm accuracy and completeness of the entered information. Extensive data quality standards 
were in place to address any systematic data issues identified. 
 
Statistical Analysis  
Baseline data were summarized descriptively. Continuous variables were reported as mean and 
standard deviation. Categorical variables were reported as absolute frequencies and percentages. 
SAMe-TT2R2 scores were derived from the patient characteristics at baseline. Baseline characteristics for 
patients treated with oral anticoagulants were described based on SAMe-TT2R2 score (>2 versus ≤2). To 
compare these groups, standardized differences were used. The focus will be on the variables with 
highest standardized differences, while differences ≤10% in absolute value will be considered as 
balanced between the groups
5
.  
We performed a log-binomial regression analysis to estimate risk ratios in the cohort of patients who 
were anticoagulated to identify the association between SAMe-TT2R2 score and prescription of VKA. We 
use the term “probability ratio” rather than “risk ratio” as our measure describes drug use rather than 
adverse outcomes. Both univariate and multivariate log-binomial regression analyses were performed to 
evaluate the crude as well as the adjusted probability ratios together with 95% confidence intervals 
(CIs). The variables included in this analysis were the SAMe-TT2R2 score and other covariates which are 
not SAMe-TT2R2 components, as follows: the type of atrial fibrillation (paroxysmal vs. persistent vs. 
permanent), body mass index class, reimbursement status, geographical region (Asia, Europe, North 
America, Latin America), other comorbidities [prior bleeding and cancer] and alcohol abuse. Statistical 
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The baseline characteristics and their standardized differences by baseline SAMe-TT2R2 score are 
summarized in table 1. Among 21,597 patients who were enrolled in 38 countries, there were 21,248 
who were eligible for the analysis. Of these, 17,465 (82.2%) were treated with oral anticoagulation 
(45.0% women) and were included in the analysis. Among OAC treated patients, 4,828 (27.6%) received 
VKA and 12,637 (72.4%) received NOAC. Out of 17,465 OAC treated patients, 11,884 (68.0%) patients 
had SAMe-TT2R2 score of ≤2 and 5,581 (32.0%) with a score of >2.  
Patients with a SAMe-TT2R2 score of ≤2 were older (mean age (±SD) 72.4±9.4 vs 68.3±11.4) and were 
more often men (58.5% vs 47.8%) as compared to those with SAMe-TT2R2 score >2. The mean CHADS2 
score was 1.9±1.1 and the mean CHA2DS2-VASc was 3.2±1.5 in both SAMe-TT2R2 groups. The mean HAS-
BLED was 1.3±0.8 in patients with SAMe-TT2R2 score of ≤2 and 1.2±0.9 for patients with SAMe-TT2R2 
score of >2.  
 
Clinical risk profile and SAMe-TT2R2 score 
Patients from Europe accounted for 60.8% of those with a SAMe-TT2R2 score of ≤2; 38.9% and 35.0% of 
patients with a SAMe-TT2R2 score >2 were from Asia and Europe, respectively. Fewer patients in the 
SAMe-TT2R2 score of ≤2 underwent NVAF ablation (0.9% vs 4.2%) and there was a higher prevalence of 
hyperlipidemia (42.7% vs 36.6%) and cancer (11.7% vs 7.2%) compared to those with score of >2. There 
was high prevalence of congestive heart failure (25.7% vs 20.4%), diabetes mellitus (28.4% vs 21.7%), 
hepatic disease (2.5% vs 0.8%) and chronic kidney disease (27.1% vs 22.0%) in SAMe-TT2R2 score >2 
versus those with a SAMe-TT2R2 score ≤2. 
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The proportion of patients treated with VKAs was 28.0% with a SAMe-TT2R2 score of >2 and 27.5% with 
a score of ≤2. Patients from Europe and Latin America who had a SAMe-TT2R2 score >2 were less often 
prescribed VKA compared with a SAMe-TT2R2 score ≤2 (21.0% vs. 28.2%, for Europe, standardized 
difference: -0.169; 27.8% vs. 41.1%, for Latin America, standardized difference: -0.283).  Patients from 
North America with a SAMe-TT2R2 score >2 were more often prescribed VKA compared with those with 
a SAMe-TT2R2 score ≤2 (14.3% vs. 9.6%, respectively, standardized difference: -0.147) (figure 1).  
 
SAMe-TT2R2 score and VKA use: Enrolment year 
There were no important differences in the prescription rate of VKAs between patients with a SAMe-
TT2R2 score >2 versus those with a score of ≤2 with regard to the enrollment year (26.4% vs. 23.5%, for 
2014, standardized difference: 0.067; 23.0% vs. 26.4%, for 2015, standardized difference: -0.079; 22.3% 
vs. 19.1%, for 2016, standardized difference: 0.079) (figure 2).     
 
Multivariable analysis 
In the multivariable analysis, patients with a SAMe-TT2R2 score >2 were less frequently prescribed VKA 
compared with patients with a score ≤2 (adjusted probability ratio 0.907; 95%CI: (0.856 , 0.961). Factors 















This is the first global study to assess the association between the SAMe-TT2R2 score and the type of oral 
anticoagulant use in a large, prospective, multinational cohort of non-valvular AF patients 
anticoagulated in routine clinical practice. We found no clear association between the SAMe-TT2R2 score 
and anticoagulant selection. 
The lack of clear association between the SAMe-TT2R2 score and anticoagulant selection may indicate 
that other factors, not captured entirely by the SAMe-TT2R2 likely have more influence on prescriptive 
choices in clinical practice. Such a factor may be the safety and efficacy profile of VKAs and NOACs. 
There is solid evidence from randomized controlled trials, as well as from real-world studies, showing 
that NOACs are safer and at least as effective as VKAs
6-8
. Accordingly, current clinical practice guidelines 
recommend NOACs in preference to VKA
2, 9, 10
. Due to overwhelming evidence favoring NOACs over 
VKAs, treating physicians may have largely adopted the related recommendations and prefer to start 
directly with a NOAC amongst NOAC-eligible NVAF patients, even in patients with a favorable SAMe-
TT2R2 score who would be expected to maintain a good level of anticoagulation control on VKA. This is in 
line with recent reports of sharply increasing trends of NOAC prescription over VKA worldwide
11-14
.  
Another potential explanation for the results of our analysis is that although several validation studies in 
different populations suggest that the SAMe-TT2R2 score can predict the quality of anticoagulation in 
NVAF patients, there is still no trial evidence that a SAMe-TT2R2-guided strategy for the selection of the 
type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. In 
this context, a large randomized trial that assesses a SAMe-TT2R2-guided strategy on quality of 
anticoagulation and on clinical outcomes (e.g., thromboembolism and bleeding) would determine its 

















While we did not perform region-specific analyses, the large sample size of prospectively recruited 
patients from nearly 50 countries with extensive data quality review and broad physician and site 















In this large, prospective, multinational cohort of non-valvular AF patients anticoagulated in routine 
clinical practice, we found no clear association between the SAMe-TT2R2 score and anticoagulant 
selection. The lack of clear association between the SAMe-TT2R2 score and anticoagulant selection may 
be attributed to the relative efficacy and safety profiles between NOACs and VKAs, as well as to the 
absence of trial evidence that a SAMe-TT2R2-guided strategy for selection of the type of anticoagulation 
in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is 
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Table 1: Baseline characteristics and their standardized differences by baseline SAMe-TT2R2 score 
for eligible anticoagulated patients in Phase III.  
 SAMe-TT2R2 ≤2 SAMe-TT2R2 >2 Standardized 
difference 
 n=11,884 n=5,581  
Demographics    
Age, mean±SD, years 72.4±9.4 68.3±11.4 −0.3920 
Female gender 4,936 (41.5%) 2,915 (52.2%) 0.2156 
Race    
White 11,351 (95.5%) 1,546 (27.7%) -1.9450 
Asian 330 (2.8%) 2,181 (39.1%) 0.9972 
Black/African American 20 (0.2%) 300 (5.4%) 0.3213 
Insurance status    
Private 1,717 (14.4%) 835 (15.0%) 0.0145 
Statutory / federal insurance 8,871 (74.6%) 4,002 (71.7%) -0.0664 
Self-pay / no coverage 429 (3.6%) 416 (7.5%) 0.1687 
Comorbidities    
Body mass index (kg/m
2
), mean±SD 29.39±6.41 27.76±6.40 -0.2553 
Dyslipidemia 5,077 (42.7%) 2,040 (36.6%) -0.1264 
Hepatic disease 91 (0.8%) 142 (2.5%) 0.1398 
Congestive heart failure 2,424 (20.4%) 1,437 (25.7%) 0.1273 
NYHA I 203 (8.4%) 138 (9.6%) 0.0430 
NYHA II 1,325 (54.7%) 759 (52.8%) -0.0370 
NYHA III 520 (21.5%) 316 (22.0%) 0.0131 
NYHA IV 45 (1.9%) 60 (4.2%) 0.1359 
Ejection fraction ≤40% 973 (40.1%) 596 (41.5%) 0.0272 
Diabetes mellitus 2,574 (21.7%) 1586 (28.4%) 0.1565 
Arterial hypertension 8,950 (75.3%) 4,331 (77.6%) 0.0540 
Abnormal kidney function 181 (1.5%) 97 (1.7%) 0.0170 
Previous stroke 1,135 (9.6%) 656 (11.8%) 0.0715 
Transient ischemic attack 651 (5.5%) 185 (3.3%) -0.1057 
Pulmonary embolism 70 (0.6%) 39 (0.7%) 0.0137 
Deep venous thrombosis 168 (1.4%) 53 (0.9%) -0.0430 
Non-CNS arterial embolism 49 (0.4%) 20 (0.4%) -0.0087 
Smoking    
Non smoker 6,821 (57.4%) 3,078 (55.2%) -0.0453 
Current smoker 180 (1.5%) 1,369 (24.5%) 0.7277 
Past smoker 4,482 (37.7%) 985 (17.6%) -0.4602 
Alcohol abuse (≥8 Units/week) 883 (7.4%) 357 (6.4%) -0.0407 
Coronary artery disease 2,052 (17.3%) 998 (17.9%) 0.0162 
Myocardial infarction 1,127 (9.5%) 476 (8.5%) -0.0333 
Periphery arterial disease 348 (2.9%) 165 (3.0%) 0.0017 
Prior bleeding 610 (5.1%) 252 (4.5%) -0.0288 
Cancer 1392 (11.7%) 404 (7.2%) -0.1532 
Creatinine clearance (ml/min), mean±SD 86.0±200.5 80.3±39.9 -0.0394 
Creatinine clearance <15ml/min 70 (0.6%) 42 (0.8%) 0.0200 
Creatinine clearance 15 to <30ml/min 188 (1.6%) 122 (2.2%) 0.0444 
Creatinine clearance 30 to <50ml/min 1,235 (10.4%) 722 (12.9%) 0.0793 
Creatinine clearance 50 to <80ml/min 3,854 (32.4%) 1,723 (30.9%) -0.0335 
Creatinine clearance ≥80ml/min 4,215 (35.5%) 1,893 (33.9%) -0.0326 
Type of NVAF    
Paroxysmal 6,204 (52.2%) 3,115 (55.8%) 0.0725 
Persistent 4,354 (36.6%) 1,947 (34.9%) -0.0365 
Permanent 1,326 (11.2%) 519 (9.3%) -0.0614 
Categorization of NVAF    
Symptomatic 3,475 (29.2%) 1,930 (34.6%) 0.1148 
Minimally symptomatic 3,930 (33.1%) 1,893 (33.9%) 0.0180 
Asymptomatic 4,479 (37.7%) 1,758 (31.5%) -0.1304 
Type of site    
GP/primary care 600 (5.0%) 337 (6.0%) 0.0433 









   
 
17
Community hospital 3,679 (31.0%) 1,731 (31.0%) 0.0013 
University hospital 3,439 (28.9%) 1,910 (34.2%) 0.1139 
Out-patient health care centre 184 (1.5%) 79 (1.4%) -0.0110 
Anticoagulation clinic 74 (0.6%) 28 (0.5%) -0.0162 
Physician specialty    
GP/PCP/Geriatrician 651 (5.5%) 148 (2.7%) -0.1435 
Cardiologist 9,702 (81.6%) 5,077 (91.0%) 0.2739 
Internist 594 (5.0%) 144 (2.6%) -0.1269 
Neurologist 320 (2.7%) 133 (2.4%) -0.0197 
CHADS2 score,  mean±SD 1.9±1.2 1.9±1.1 0.0222 
CHADS2 score = 0 964 (8.1%) 394 (7.1%) -0.0397 
CHADS2 score = 1 4,051 (34.1%) 1,809 (32.4%) -0.0355 
CHADS2 score ≥ 2 6,868 (57.8%) 3,378 (60.5%) 0.0557 
CHA2DS2-VASc score, mean±SD 3.2±1.5 3.2±1.5 -0.0364 
CHA2DS2-VASc score = 1 1,408 (11.8%) 718 (12.9%) 0.0309 
CHA2DS2-VASc score ≥ 2 10,476 (88.2%) 4,863 (87.1%) -0.0309 
HAS-BLED, mean±SD 1.3±0.8 1.2±0.9 -0.1571 
HAS-BLED <3 9,846 (82.9%) 4,616 (82.7%) -0.0038 
HAS-BLED ≥3 898 (7.6%) 381 (6.8%) -0.0282 
Treatment with amiodarone 825 (6.9%) 1640 (29.4%) 0.6085 
Antithrombotic prescription    
VKA alone 2,795 (23.5%) 1,291 (23.1%) -0.0092 
VKA + antiplatelets 470 (4.0%) 272 (4.9%) 0.0447 
NOAC alone 7,434 (62.6%) 3,486 (62.5%) -0.0019 
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Table 2: Log-Binomial regression analysis for the prediction of VKA prescription. Only patients who  
were anticoagulated, were included in the analysis. 
 
        Univariate analysis Multivariate analysis 






Relative risk (95% CI) 
for prescription of VKA 
use 
Relative risk  
(95% CI) 
for prescription of VKA use 
Baseline SAMe-TT2R2           




Score ≤2 11884 3265 (27.5) 8619 (72.5) 1.0  
(ref) 
 1.0  
(ref) 
 
Region      




Europe 9182 2747 (29.9) 6435 (70.1) 1.0  
(ref) 
 1.0  
(ref) 
 








Type of AF      
Paroxysmal 9319 2179 (23.4) 7140 (76.6)  1.0  
(ref) 
 1.0  
(ref) 
 








BMI class      
<18.5 199 58  
(29.1) 




18.5−<25 4484 1288 (28.7) 3196 (71.3) 1.0  
(ref) 
 1.0  
(ref) 
 












Prior bleeding      








Alcohol abuse      








Cancer      








Medical treatment reimbursed by 









































Figure 2: Proportion of patients treated with VKA and NOAC by baseline SAMe-TT2R2 score and 
enrollment year.  
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